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in relation to the disease, it is essential to 
compare the activity of T cells from blood 
and patch test sites simultaneously in the 
same patient, as mentioned above.
Third, and most important, in light 
of allergic patients’ hapten-specific Th2 
cytokine profile, additional studies should 
measure Ab titers to hapten/hapten-
bound protein complexes. Such studies 
would open the door for immuno logical 
studies on the cooperative effects of Abs, 
antigen-specific T cells, and immune 
complexes and their role in the path-
ology of contact derma titis. This raises 
the possibility that haptens not only gen-
erate hapten-specific T cells but also can 
initiate the production of hapten-specific 
Abs. Abs specific for low-molecular-
weight compounds have been reported 
previously (Das et al., 1980; Amos et al., 
1978). In the latter case it can be postu-
lated that, in addition to T-cell-mediated 
hypersensitivity reactions, hapten–Ab 
complexes can give rise to type III hyper-
sensitive reactions.
concluding remarks
These immunochemical studies do not 
necessarily ring the death knell for the 
patch test. However, the data should 
certainly encourage other researchers to 
develop more objective parameters for 
improving the patch test, stimulate the 
development of novel alternative in vitro 
tests, and enhance the understanding 
of structure–activity relationships in the 
pathophysiology of contact dermatitis.
The work reported in this and similar 
studies has opened the door to apply-
ing combined chemical immunological 
techniques to (i) study the different 
types of chemical modification of small 
chemicals that render them allergenic, 
nonallergenic, or simple irritants and (ii) 
elucidate the mechanism of chemically 
induced dermatitis in depth compared 
with that of irritant contact dermatitis.
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Multiple Genes and Locus 
Interactions in susceptibility  
to Vitiligo
Aaron G. Smith1 and Richard A. Sturm1
Refining the position of loci on chromosomes 7 and 9 previously linked with 
generalized vitiligo or vitiligo-associated autoimmune diseases presenting in 
families has been performed by high-density single-nucleotide polymorphism 
(snP) genotyping. Investigation of the genetic interaction among these loci (and 
with a previously identified susceptibility gene, NLRP1, on chromosome 17) as 
risk factors for vitiligo demonstrates the complex nature of this disease.
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The biological basis of the depigment-
ing condition known as vitiligo has 
been an intractable problem to con-
front. The difficulty lies in the absence 
of the cells responsible for the disease, 
posing the conundrum of how to study 
something that isn’t there. Patients pre-
senting with vitiligo have a progressive 
loss of melanocytes, predominantly in 
areas of skin subject to physical abra-
sion or at pressure points, leading to 
white patches appearing on the body. 
In normal physiological circumstances, 
melanin pigment is generated by the 
melanocytes and transferred to the 
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markers in regions 7p13, 7q11, and 
9q22 were found to be significantly 
associated with generalized vitiligo, 
with tagging SNPs for these regions 
represented by rs6960920, rs734930, 
and rs4744411, respectively. The 
investigators next examined the poten-
tial for genetic interaction for these 
independently identified loci using 
two-way tests (and three-way tests in 
the context of the previously identified 
NLRP1 gene tagged by the rs6502867 
SNP). Notably, all three SNPs showed 
significant interaction with the NLRP1 
gene in predicting the generalized 
vitiligo phenotype (Jin et al., 2010). 
Perhaps future studies of gene interac-
tions in familial susceptibility to vitili-
go should also test GSTM1 and GSTT1 
null alleles (Liu et al., 2009) as modi-
fiers of its penetrance.
Despite refining the previous genet-
ic associations with these SNPs on 
chromo somes 7 and 9, identifying the 
loci in proximity to the three tagging 
SNPs does not immediately provide bio-
logical insight into the mechanistic basis 
underlying the pathology of, progres-
sion of, or susceptibility to vitiligo. The 
SNP cluster in 7p13 lies between the 
CAMK2B and the NUDCD3 genes. The 
reported role of the CAMK2B gene in 
platelet-activating factor (PAF)-induced 
macrophage priming offers this gene as 
one logical candidate for further exam-
ination. The proximity of the 7q11 SNP 
to AUTS2, a putative autism candidate 
gene, and the position of the 9q22 
SNP—within an intron of a predicted 
open reading frame, C9orf3, of unknown 
function—must also be pursued.
Given our scant knowledge of the 
biological role of these genes, their con-
tribution to vitiligo susceptibility and 
development is impossible to predict. 
Future investigation into the function of 
these genes and gene products and the 
influence they may have on melano-
cyte biology will be essential to dissect 
what role, if any, they play in vitiligo. 
Unfortunately, although SNPs identified 
in association studies provide marker 
flags to indicate genes directly linked to 
a given phenotype, rarely do such SNPs 
lie in the protein-coding exons, and the 
challenge remains to identify the actual 
causative changes responsible in the 
genome. Given the complexity inherent 
the field (Waterman et al., 2009). 
Oxidative damage—as a consequence 
of metabolic dysregulation and pro-
duction of toxic metabolites during 
melanogenesis occurring in the mel-
anocytes of vitiligo patients—has 
also been suggested to exert some 
pathological influence on this dis-
ease. Of interest is the recent genetic 
association of vitiligo with null-allele 
polymorphisms in the glutathione 
S-transferase (GST) enzymes observed 
in a Chinese population (Liu et al., 
2009), which showed nullizygous 
individuals to be at greater risk for the 
disease.
Although candidate analyses such 
as GSTM1 and GSTT1 geno typing pro-
vide some tantalizing clues, un biased 
genetic approaches may provide bet-
ter insight into the biology of vitiligo. 
For comparison, a whole-genome 
linkage scan in family cohorts with 
multiple members presenting with 
vitiligo and/or a cluster of associated 
autoimmune diseases has previously 
identified regions on chromosomes 
1, 7, and 17 as being associated with 
vitiligo, and a suggestive linkage was 
observed for loci on chromosomes 8, 9, 
11, 13, 19, and 22 (Spritz et al., 2004). 
Subsequent focus on chromosome 17 
linkage using single-nucleotide poly-
morphism (SNP) markers revealed hits 
within the NLRP1 gene, which encodes 
the NALP1 protein, identifying this as 
the vitiligo susceptibility locus on this 
chromosome (Jin et al., 2007). The 
work of Jin and colleagues (2010) pub-
lished in this issue extends this study 
to provide clearer evidence of linkage 
and fine mapping for some of the other 
regions in these families, allowing 
testing for genetic interactions among 
these loci using SNP markers.
First, reassessment of their ear-
lier data allowed Jin et al. to exclude 
the previously identified loci on 
chromosomes 8, 13, 19, and 22. 
Moreover, fine-scale mapping of 867 
and 304 SNPs—spanning linkage 
regions on chromosomes 7 and 9, 
respectively—increased support for 
the association of these loci with the 
vitiligo and associated autoimmune 
phenotypes. Specifically, using trans-
mission disequilibrium and family-
based association statistical tests, SNP 
skin complexion and hair coloration. 
The loss of melanocytes in vitiligo 
leads to several distinctive features, 
although the lack of an identifiable 
initiating event in most cases is anoth-
er puzzling element. The disease pres-
ents clinically as generalized vitiligo, 
which is more common, or segmental 
vitiligo, which generally has an earlier 
age of onset (Taieb and Picardo, 2009). 
Epidemiological studies have shown 
that vitiligo affects both sexes equally 
and that its frequency is unaffected 
by skin type or ethnic background 
(although it is more obvious in darker 
complexions).
The events initiating vitiligo are still 
under debate, but it is generally accept-
ed as an acquired disorder (Boissy and 
Spritz, 2009). It usually occurs spo-
radically but with greater frequencies 
among parents, siblings, and other 
near relatives of affected individuals, 
suggesting that familial, nonmendelian 
genetic factors play roles. In addition, 
25–30% of patients present one other 
autoimmune disease, and an increased 
frequency of a range of such conditions 
is manifest in first-degree relatives. 
Efforts to identify the genes involved 
in vitiligo risk have followed a trail of 
false leads based on best guesses and 
replication failures, with no primary 
underlying monogenic basis identified 
so far in any population.
Immunological factors that con-
tribute to the disease have been stud-
ied by looking for autoantigens and 
circulating autoreactive T-cells to 
melanocytes. Although anti bodies 
to various melanocytic proteins 
have been detected, the role of these 
autoantibodies as a primary cause 
or a secondary effect of melanocyte 
destruction is uncertain, and their 
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enzymes that regulate skin pigmentation
Melanin synthesis by melanocytes is one 
of the most important parameters regu-
lating skin pigmentation (Yamaguchi et 
al., 2007a), and more than 150 pigment 
genes have now been identified. The 
cosmetic industry has developed numer-
ous hypopigmenting (depigmenting or 
whitening) reagents to suppress melanin 
synthesis in order to meet the needs of 
customers with hyperpigmenting condi-
tions such as chloasma (melasma) and/
or ephelides (freckles) (Solano et al., 
2006). There is also a demand for hyper-
pigmenting (artificial tanning) reagents 
to treat vitiligo and other hypopigment-
ing diseases, and there are societies in 
which tanning is perceived as beautiful 
and healthy. Taking together these obser-
vations, methods of controlling melanin 
synthesis have considerable significance 
for patients with pigmentary disorders 
and in the general marketplace.
Enzymes involved in melanin synthe-
sis include tyrosinase, tyrosinase-related 
protein-1 (TYRP1), and dopachrome 
tautomerase (DCT) (Yamaguchi and 
Hearing, 2009). Among these enzymes 
in the tyrosinase family, tyrosinase 
in mammalian gene regulation, it is high-
ly likely that SNPs that alter the regula-
tion of gene expression may function at 
some distance from the target gene. This 
concept is exemplified in the context of 
melanocyte biology by recent associa-
tion studies into pigmentation regulation 
in the eye. The presence of a single SNP 
located within intron 86 of the HERC2 
gene was found to be the major determi-
nant of blue/brown eye-color phenotypes 
in humans (Sturm et al., 2008). Although 
this finding may have provided impe-
tus to investigate the role of this gene in 
melanocyte function, prior knowledge 
of melanocyte biology suggests that this 
SNP is likely to regulate the expression 
of the neighboring OCA2 gene, with its 
role already firmly established in the pro-
cess of pigmentation. 
To fully appreciate and extend these 
findings, the genetic associations and 
locus interactions of these candidate sus-
ceptibility genes must also be examined 
in the wider context of the autoimmune 
diseases that accompany vitiligo.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ReFeRenCes
Boissy RE, Spritz RA (2009) Frontiers and 
controversies in the pathobiology of vitiligo: 
separating the wheat from the chaff. Exp 
Dermatol 18:583–5
Jin Y, Mailloux CM, Gowan K et al. (2007) NALP1 
in vitiligo-associated multiple autoimmune 
disease. N Engl J Med 356:1216–25
Jin Y, Riccardi SL, Gowan K et al. (2010) Fine-
mapping of vitiligo susceptibility loci on 
chromosomes 7 and 9 and interactions with 
NLRP1 (NALP1). J Invest Dermatol 130:774–83
Liu L, Li C, Gao J et al. (2009) Genetic 
polymorphisms of glutathione S-transferase and 
risk of vitiligo in the Chinese population. J Invest 
Dermatol 129:2646–52
Spritz RA, Gowan K, Bennett DC et al. 
(2004) Novel vitiligo susceptibility loci 
on chromosomes 7 (AIS2) and 8 (AIS3), 
confirmation of SLEV1 on chromosome 17, 
and their roles in an autoimmune diathesis. 
Am J Hum Genet 74:188–91
Sturm RA, Duffy DL, Zhao ZZ et al. (2008) A single 
SNP in an evolutionary conserved region 
within intron 86 of the HERC2 gene determines 
human blue-brown eye color. Am J Hum Genet 
82:424–31
Taieb A, Picardo M (2009) Clinical practice. Vitiligo. 
N Engl J Med 360:160–9
Waterman EA, Gawkrodger DJ, Watson PF et al. 
(2009) Autoantigens in vitiligo identified by 
the serological selection of a phage-displayed 
melanocyte cDNA expression library. J Invest 
Dermatol 130:230–40
See related article on pg 784
nADPH:Quinone Oxidoreductase-1 
as a new Regulatory enzyme That 
Increases Melanin synthesis
Yuji Yamaguchi1, Vincent J. Hearing2, Akira Maeda1  
and Akimichi Morita1
Most hypopigmenting reagents target the inhibition of tyrosinase, the key 
enzyme involved in melanin synthesis. In this issue, Choi et al. report that 
nADPH:quinone oxidoreductase-1 (nQO1) increases melanin synthesis, 
probably via the suppression of tyrosinase degradation. Because nQO1 
was identified by comparing normally pigmented melanocytes with 
hypopigmented acral lentiginous melanoma cells, these results suggest 
various hypotheses regarding the carcinogenic origin of the latter. 
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plays the critical role in melanin syn-
thesis, and various factors, including 
the copper-transporter ATP7A, have 
the capacity to modulate its enzymat-
ic activity (Setty et al., 2008). Indeed, 
most hypopigmenting reagents are 
intended to suppress tyrosinase activ-
ity. Additionally, two variants of oculo-
cutaneous albinism in humans (OCA1A 
and OCA1B) are caused by mutations in 
tyrosinase. Tyrosinase is the rate-limiting 
enzyme that mediates hydroxylation 
of tyrosine to dopaqui none and the 
oxidation of 5,6-dihydroxyindole (DHI) 
to indole-5,6-quinone, which pro-
duces eumelanin (Figure 1). DCT is a 
tautomerase that converts dopachrome 
to DHI-2-carboxylic acid (DHICA), 
whereas TYRP1 is a DHICA oxidase that 
further stimulates eumelanin synthesis. 
Consequently, melanogenic enzymes 
that act within melanosomes are critical 
for the production of the pigmented bio-
polymer melanin.
nQo1 as an enhancer  
of tyrosinase activity
Yoon’s group has identified NADPH: 
quinone oxidoreductase-1 (NQO1) 
